Astrid Borkowski - Feb 1, 2023 Form 4 Insider Report for HilleVax, Inc. (HLVX)

Role: Chief Medical Officer
Signature: /s/ Paul Bavier, Attorney-in-Fact for Astrid Borkowski
Stock symbol: HLVX
Transactions as of: Feb 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/3/2023, 03:22 PM
Previous filing: Apr 28, 2022
Next filing: Jun 23, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HLVX	Common Stock	Award	$0	+51.3K	+30.48%	$0.00	220K	Feb 1, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HLVX	Stock Option (Right to Buy)	Award	$0	+77K		$0.00	77K	Feb 1, 2023	Common Stock	77K	$18.00	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") which will vest as to 25% of the total number of RSUs granted on each of the first four anniversaries of February 1, 2023, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date.
F2	Includes 341 shares acquired under the HilleVax, Inc. employee stock purchase plan on November 15, 2022.
F3	The option is exercisable as it vests. The option will vest with respect to 25% of the shares of common stock on February 1, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.